SCHEMBL2156502

SCHEMBL2156502

c1ccc(Oc2ccc(N3CCNCC3)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 1.00
ADRB1 P08588 6/20 0.68
HTR3E A5X5Y0 4/20 0.68
HTR3B O95264 4/20 0.68
HTR3A P46098 4/20 0.68
HTR3D Q70Z44 4/20 0.68
HTR3C Q8WXA8 4/20 0.68
SIGMAR1 Q99720 4/20 0.68
HTR1A P08908 3/20 0.60
SLC6A2 P23975 2/20 0.60
SLC6A4 P31645 2/20 0.60
SLC6A3 Q01959 2/20 0.60
HTR5A P47898 1/20 0.56
HTR6 P50406 2/20 0.56
USP2 O75604 1/20 0.56
ALDH1A1 P00352 1/20 0.56
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
SCN4A P35499 1/20 0.52
SCN9A Q15858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2881150 0.98 LTA4H (0.96) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL4671118 0.86 LTA4H (0.75) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL18553712 0.84 LTA4H (0.72) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL14465246 0.84 LTA4H (0.72) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL2881283 0.84 ADRB1 (0.89) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL2881718 0.84 ADRB1 (0.79) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL13234979 0.84 LTA4H (1.00) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL19597620 0.84 LTA4H (0.72) LTA4HADRB1HTR3EHTR3BHTR3A
SCHEMBL2784743 0.82 LTA4H (0.70) LTA4HUSP2ALDH1A1TSHRHSD17B10
Hydrochloric Acid SCHEMBL2881375 0.82 LTA4H (0.97) LTA4HADRB1HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925637-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2024-03-12 US claimed
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2022-02-17 US claimed
US-10980801-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2021-04-20 US claimed
US-20200253958-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2020-08-13 US claimed
US-11925637-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2024-03-12 US disclosed
EP-4028403-B1 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2023-11-22 EP disclosed
US-11814375-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2023-11-14 US disclosed
EP-4028403-A1 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS F. Hoffmann-La Roche AG (CH) 2022-07-20 EP disclosed
CN-114269755-A 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one compounds as MAGL inhibitors 豪夫迈·罗氏有限公司 2022-04-01 CN disclosed
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2022-02-17 US disclosed
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE SRX CARDIO, LLC 2022-02-17 US disclosed
US-10980801-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use SRX CARDIO, LLC (US) 2021-04-20 US disclosed
EP-0974573-A1 PHENYLPROPENONE COMPOUNDS AND MEDICINES CONTAINING THE SAME Kabushiki Kaisha Yakult Honsha (JP) 2000-01-26 EP disclosed
US-5998412-A ANTIARTHRITIC AGENTS; OSTEOPOROSIS SYNTEX (U.S.A.) INC. (US) 1999-12-07 US disclosed
US-5723475-A Arylpiperidine and arylpiperazine derivatives and medicament containing the same SUNTORY LIMITED (JP) 1998-03-03 US disclosed
EP-0757986-A1 ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-12 EP disclosed
EP-0755923-A1 AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR SUNTORY LIMITED (JP) 1997-01-29 EP disclosed
US-5084456-A Analgesics SCIENCE ET ORGANISATION (FR) 1992-01-28 US disclosed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US disclosed
EP-0076996-A1 Carboxylic-acid derivatives, process for their preparation and medicines containing them Roche Diagnostics GmbH (DE) 1983-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200253958-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE PCSK9, LDLR, PCSK7 LTA4H 1131/4885ADRB1 1401/4885HTR3E 1341/4885
US-11814375-B2 Heterocyclic compounds CYP1B1, CYP1A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 LTA4H 1217/4885ADRB1 748/4885HTR3E 3020/4885
US-20220047582-A1 PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE PCSK9, LDLR, PCSK7 LTA4H 1131/4885ADRB1 1401/4885HTR3E 1341/4885
US-10980801-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use PCSK9, LDLR, PCSK7 LTA4H 1131/4885ADRB1 1401/4885HTR3E 1341/4885
US-11925637-B2 Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use PCSK9, LDLR, PCSK7 LTA4H 1131/4885ADRB1 1401/4885HTR3E 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.